{"entity":{"id":"nct06952478","kind":"trial","name":"A Study to Compare Pharmacokinetics, Efficacy and Safety of Subcutaneous CT-P44 and Darzalex Faspro in Combination With Lenalidomide and Dexamethasone","aka":[],"tldr":"A phase 3 trial of Daratumumab in multiple myeloma, run by Celltrion, now recruiting.","summary":"A Study to Compare Pharmacokinetics, Efficacy and Safety of Subcutaneous CT-P44 and Darzalex Faspro in Combination With Lenalidomide and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma is a phase 3 interventional study registered as NCT06952478 by Celltrion, with 486 participants planned, started 2025-08-12 and due to reach its primary completion in 2027-11-15. Interventions recorded: CT-P44(Daratumumab), Darzalex Faspro(Daratumumab). Conditions listed: Refractory or Relapsed Multiple Myeloma. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06952478","url":"https://clinicaltrials.gov/study/NCT06952478"}],"tags":["ctgov-ingest"],"related":[],"cancers":["multiple-myeloma"],"sections":[],"technologies":[],"targets":[],"drugs":["daratumumab"],"companies":["celltrion"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06952478","phase":"3","setting":"A Double-Blind, Randomized, Active-Controlled, Parallel-group, Phase 1/3 Study to Compare Pharmacokinetics, Efficacy and Safety of Subcutaneous CT-P44 and Darzalex Faspro in Combination With Lenalidomide and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma","sponsor":"Celltrion","enrolled":486,"outcomes":[]},"route":"/trials/nct06952478/","neighbours":{"cancer":[{"id":"multiple-myeloma","kind":"cancer","name":"Multiple myeloma","route":"/cancers/multiple-myeloma/"}],"drug":[{"id":"daratumumab","kind":"drug","name":"Daratumumab","route":"/drugs/daratumumab/"}],"company":[{"id":"celltrion","kind":"company","name":"Celltrion","route":"/companies/celltrion/"}]}}